Evidence map›Paper›PMID 35384481›Full record

ArticleSchmerz (Berlin, Germany)2023

[Cannabinoids reduce opioid use in older patients with pain : Retrospective three-year analysis of data from a general practice].

K Gastmeier, A Gastmeier, F Rottmann, T Herdegen, R Böhm

Open access · hybridAbstract readEnglish Abstract
In one paragraph

Article in Schmerz (Berlin, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

K GastmeierSchmerzpraxis, Karl-Marx-Str. 42, 14482, Potsdam, Deutschland.
A GastmeierFacharztpraxis Bäkemühle, Zehlendorfer Damm 217, 14532, Kleinmachnow, Deutschland.
F RottmannInstitut für Experimentelle und Klinische Pharmakologie, Christian-Albrechts-Universität zu Kiel, Arnold-Heller-Straße 3, Haus U37, 24105, Kiel, Deutschland.
T HerdegenInstitut für Experimentelle und Klinische Pharmakologie, Christian-Albrechts-Universität zu Kiel, Arnold-Heller-Straße 3, Haus U37, 24105, Kiel, Deutschland. t.herdegen@pharmakologie.uni-kiel.de.
R BöhmInstitut für Experimentelle und Klinische Pharmakologie, Christian-Albrechts-Universität zu Kiel, Arnold-Heller-Straße 3, Haus U37, 24105, Kiel, Deutschland.
Kiel University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRelevant data for the prescription and therapeutic effects of medical cannabinoids (CAM) are still missing in everyday medicine especially for elderly and geriatric patients. AIM OF THE STUDY: Documentation of prescription (duration, age) of CAM (dronabinol, nabiximols, cannabinoid extracts) and co-medicated opioids in a doctor's office specializing in pain.

methodsAnalysis of the consumption of opioids (morphine equivalent) and CAM (THC equivalent) for age and gender.

resultsIn all, 178 patients with chronic pain were treated for a period of 366 days (median; range 31-2590 days). Median age was 72 years (26-96 years); 115 were women (64.8%). Of these, 34 were younger than 65 years, 42 were 65-80 years and 40 were more than 80 years old. Of the 63 men, 29 were younger than 65 years, 24 were 65-80 years and 10 were older than 80 years. Indications for CAM were chronic pain and the limitations for opioids because of side effects and worsening of quality of life. To total of 1001 CAM were prescribed, 557 (55.6%) dronabinol as liquid, 328 (32.7%) as full spectrum extracts and 66 (6.6%) as oro-mucosal nabiximols spray. 50 prescriptions (5%) contained more than one CAM simultaneously. The daily consumption of dronabinol liquor and extracts were 9.6 mg/day (median), and of spray 13.6 mg. The dosage over time did not change in patients older than 64; in younger patients, there was a non-significant increasing trend. Women requested lower THC dosages compared to men (8.1 mg vs. 14.8 mg). Furthermore, 10 patients (5.6%) stopped CAM because of failing effectivity, 7 (3.9%) because of failing cost coverage and only 5 because of adverse side effects. 115 patients (65%) with CAM also received opioids a median 65 mg/day morphine equivalents. This opioid dosage was significantly reduced in course of time by 24 mg/day morphine equivalents or 50%. This reduction was independent on CAM dosage, age and gender. DISCUSSION: Patients with chronic pain profit from long-term CAM which safely and significantly lower the consumption of comedicated opioids, even at low dosages (< 7.5 mg/day). For women, low-dose THC may be sufficient. Older patients benefit from CAM, and adverse effects do not limit the (chronic) use and prescription of CAM in the elderly.

Indexed as

CannabinoidsChronic PainGeneral PracticeOpioid-Related DisordersAgedAged, 80 and overAnalgesics, OpioidDronabinolFemaleHumansMaleMorphineQuality of LifeRetrospective StudiesAnalgesics, OpioidCannabinoidsDronabinolMorphineEndocannabinoid systemExtractsGeriatricsOpioidsPain therapy

Identifiers

PMID35384481
PMCPMC9889530
OpenAlexW4225366137

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.